Clinical trials: FMF
Hereditary Autoinflammatory Diseases
Quality of Life in Patients With Auto-inflammatory Diseases
This qualitative interview-based study aim to build a tool to assess quality of life in patients (adults or children) suffering from 6 autoinflammatory diseases (FMF, TRAPS, CAPS, MKD, Still and PFAPA).
- Trial name
- MAI-PATIENT (NCT03569644)
- Testing
- qualitative study
- Where
- 3 sites in France
- Volunteers
- 39 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mevalonate Kinase Deficiency
Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency
Mevalonate kinase deficiency (HyperIgD syndrome, HIDS) is an inborn error of immunity caused by a block in the mevalonate pathway.
- Trial name
- NCT06497829
- Testing
- geranylgeraniol
- Where
- Czechia
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University Hospital, Motol
Familial Mediterranean Fever
is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever
Familial mediterranean fever (FMF) is common in mediterranean region. this disorder is connected with deterioration in functional performance, fitness of cardiorespiration, muscle strength, and bone mass
- Trial name
- NCT07130305
- Testing
- whole body vibration plus usual care, usual care
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Familial Mediterranean Fever
Evaluation of Bone Metabolism in Children and Adolescents With Familial Mediterranean Fever
Familial Mediterranean Fever is a chronic auto-inflammatory disease. In the context of chronic inflammation, it seems that, among others, it also affects bone density in children.
- Trial name
- FMF (NCT06034795)
- Where
- Greece
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Behcet's Syndrome
Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease
The purpose of this study is to find if Rituximab can improve severe ocular lesions of Behcet's Disease.
- Trial name
- NCT00664599
- Testing
- Rituximab, Cytotoxic Combination
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Tehran University of Medical Sciences